Cardiometabolic & kidneyCohort study
Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population
- Cohort study
- population-based
Authors' conclusion
Metabolic dysfunction-associated steatotic liver disease is an independent risk factor for MACE and is associated with a significantly increased risk of all-cause mortality.
Study context
- Population
- General population in GermanyMASLD in 37%
- Participants
- 14,575 participants
- Exposure
- MASLD vs no MASLD
- Outcome
- Incident MACE (acute myocardial infarction (AMI), stroke, CV mortality) and eMACE (MACE, incident AF, PE); all-cause mortality
- Follow-up
- 5 years
Main finding
As reported in the abstract
eMACE · 5 years
P < 0.0001
- Increased risk of major adverse cardiovascular events (MACE) with MASLD (Cox regression, stepwise adjustment)
- 62.3%
- Increased risk of extended MACE (eMACE) with MASLD (Cox regression, stepwise adjustment)
- 44.0%
Observational data: associations, not effects.
Further findings
| Outcome | HR | P value |
|---|---|---|
| All-cause mortality | 1.55 | P < 0.0001 |
Overall cohort incidence · 5 years
- 3-point MACE
- 475 (3.7%)
- eMACE
- 577 (4.9%)
Original publication
Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population. Eur J Heart Fail. Published 26 September 2025. doi:10.1002/ejhf.70053
Summarised from the published abstract; every number is checked against it